enGene Therapeutics (ENGN) Net Income (2023 - 2026)

enGene Therapeutics (ENGN) has 4 years of Net Income data on file, last reported at -$32.5 million in Q3 2026.

• For the quarter ending Q3 2026, Net Income fell 12.11% year-over-year to -$32.5 million; the trailing twelve-month figure through Jul 2026 stood at -$130.4 million (down 37.63% YoY), and the FY2025 full-year result was -$117.3 million, down 112.73% from the prior year.
• Net Income was -$32.5 million for Q3 2026 at enGene Therapeutics, down from -$30.2 million in the prior quarter.
• In the past five years, Net Income ranged from a high of -$4.7 million in Q3 2023 to a low of -$82.5 million in Q4 2023.
• A 4-year average of -$24.3 million and a median of -$24.6 million in 2025 frame the typical range for Net Income.
• The largest YoY upside for Net Income was 81.46% in 2024 against a maximum downside of 199.75% in 2024.
• enGene Therapeutics' Net Income stood at -$82.5 million in 2023, then jumped by 81.46% to -$15.3 million in 2024, then slumped by 147.6% to -$37.9 million in 2025, then climbed by 14.2% to -$32.5 million in 2026.
• Per Business Quant data, the three most recent Net Income figures were -$32.5 million in Q3 2026, -$30.2 million in Q2 2026, and -$29.8 million in Q1 2026.